Körner, C., Riesner, K., Krämer, B., Eisenhardt, M., Glässner, A., Wolter, F., . . . Nischalke, H. D. (2012). TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients. BioMed Central.
Citación estilo ChicagoKörner, Christian, et al. TRAIL Receptor I (DR4) Polymorphisms C626G and A683C Are Associated With an Increased Risk for Hepatocellular Carcinoma (HCC) in HCV-infected Patients. BioMed Central, 2012.
Cita MLAKörner, Christian, et al. TRAIL Receptor I (DR4) Polymorphisms C626G and A683C Are Associated With an Increased Risk for Hepatocellular Carcinoma (HCC) in HCV-infected Patients. BioMed Central, 2012.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.